Skip to main content

Advertisement

SpringerLink
Log in

Erlotinib/hydroxypropyl-β-cyclodextrin inclusion complex: characterization and in vitro and in vivo evaluation

  • Original Article
  • Published:
Journal of Inclusion Phenomena and Macrocyclic Chemistry Aims and scope Submit manuscript

Abstract

Erlotinib (ERL) is a drug used in epidermoid carcinoma treatment. One of the ERL drawbacks is low water solubility, which limits its use in the development of safer and effective formulations. The present study used the strategy of inclusion complexation with hydroxypropyl-β-cyclodextrin (HP-β-CD) to increase the ERL water solubility, characterize the inclusion complex physico-chemically, and evaluate the in vitro cytotoxicity and in vivo antiangiogenic effect. The data showed 1:1 molar ratio ERL:HP-β-CD inclusion complex formation both in solution and in solid state. Phase-solubility analysis showed AL-type diagrams. Isothermal titrations calorimetry and nuclear Overhauser effect spectroscopy also support that formation. Despite free ERL higher cytotoxicity, higher values were associated with the complex compared with free ERL (37.5 µM), and the complex was more cytotoxic to A431 human epidermoid carcinoma cell than to osteoblasts (non-cancerous cells). In addition, the inclusion complex exhibited antiangiogenic activity without affecting the activation and recruitment of neutrophils and macrophage. Overall, these results suggest that the ERL:HP-β-CD inclusion complex could be a promising approach for developing safe and effective ERL formulation by different routes of administration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11

Similar content being viewed by others

References

  1. Soulieres, D., Senzer, N.N., Vokes, E.E., Hidalgo, M., Agarwala, S.S., Siu, L.L.: Multicenter phase ii study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J. Clin. Oncol. 22, 77–85 (2004)

    Article  CAS  Google Scholar 

  2. Kralj, S., Rojnik, M., Kos, J., Makovec, D.: Targeting egfr-overexpressed a431 cells with egf-labeled silica-coated magnetic nanoparticles. J. Nanopart. Res. 15, 11 (2013)

    Google Scholar 

  3. Schneider, M.R., Sibilia, M., Erben, R.G.: The egfr network in bone biology and pathology. Trends Endocrinol. Metab. 20, 517–524 (2009)

    Article  CAS  Google Scholar 

  4. Mahller, Y.Y., Vaikunth, S.S., Currier, M.A., Miller, S.J., Ripberger, M.C., Hsu, Y.H., Mehrian-Shai, R., Collins, M.H., Crombleholme, T.M., Ratner, N., Cripe, T.P.: Oncolytic hsv and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. Mol. Ther. 15, 279–286 (2007)

    Article  CAS  Google Scholar 

  5. Ding, G., Liu, F., Feng, C., Xu, J., Ding, Q.: Association between the myeloperoxidase gene polymorphisms and the susceptibility to prostate cancer: a case-control study in a chinese population. Actas Urol. Esp. 37, 79–82 (2013)

    Article  CAS  Google Scholar 

  6. Tucker, S.M., Pierce, R.J., Price, R.G.: Characterization of human n-acetyl-beta-d-glucosaminidase isoenzymes as an indicator of tissue-damage in disease. Clin. Chim. Acta 102, 29–40 (1980)

    Article  CAS  Google Scholar 

  7. Balkwill, F.: Tnf-alpha in promotion and progression of cancer. Cancer Metast. Rev. 25, 409–416 (2006)

    Article  CAS  Google Scholar 

  8. Coelho, B.A., Belo, A.V., Andrade, S.P., Amorim, W.C., Uemura, G., da Silva, A.L.: N-acetylglucosaminidase, myeloperoxidase and vascular endothelial growth factor serum levels in breast cancer patients. Biomed. Pharmacother. 68, 185–189 (2014)

    Article  CAS  Google Scholar 

  9. Cohen, E.E.W., Halpern, A.B., Kasza, K., Kocherginsky, M., Williams, R., Vokes, E.E.: Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 45, E155–E160 (2009)

    Article  Google Scholar 

  10. Fan, L., Hu, L., Yang, B., Fang, X., Gao, Z., Li, W., Sun, Y., Shen, Y., Wu, X., Shu, Y., Gu, Y., Wu, X., Xu, Q.: Erlotinib promotes endoplasmic reticulum stress-mediated injury in the intestinal epithelium. Toxicol. Appl. Pharmacol. 278, 45–52 (2014)

    Article  CAS  Google Scholar 

  11. Herchenhorn, D., Dias, F.L., Viegas, C.M.P., Federico, M.H., Araujo, C.M.M., Small, I., Bezerra, M., Fontao, K., Knust, R.E., Ferreira, C.G., Martins, R.G.: Phase i/ii study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 78, 696–702 (2010)

    Article  CAS  Google Scholar 

  12. Thomas, S.M., Grandis, J.R.: Pharmacokinetic and pharmacodynamic properties of egfr inhibitors under clinical investigation. Cancer Treat. Rev. 30, 255–268 (2004)

    Article  CAS  Google Scholar 

  13. Brewster, M.E., Loftsson, T.: Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Deliv. Rev. 59, 645–666 (2007)

    Article  CAS  Google Scholar 

  14. Venturini, C.D.G., Nicolini, J., Machado, C., Machado, V.G.: Properties and recent applications of cyclodextrins. Quim. Nova 31, 360–368 (2008)

    Article  CAS  Google Scholar 

  15. Khan, A.R., Forgo, P., Stine, K.J., D’Souza, V.T.: Methods for selective modifications of cyclodextrins. Chem. Rev. 98, 1977–1996 (1998)

    Article  CAS  Google Scholar 

  16. Gould, S., Scott, R.C.: 2-hydroxypropyl-beta-cyclodextrin (hp-beta-cd): a toxicology review. Food Chem. Toxicol. 43, 1451–1459 (2005)

    Article  CAS  Google Scholar 

  17. Yan, J., Li, Q.F., Wang, L.S., Wang, H., Xiao, F.J., Yang, Y.F., Wu, C.T.: Methyl-beta-cyclodextrin induces programmed cell death in chronic myeloid leukemia cells and combined with imatinib, produces a synergistic downregulation of erk/spk1 signaling. Anticancer Drugs 23, 22–31 (2012)

    Article  CAS  Google Scholar 

  18. Lee, Y.H.P., Sathigari, S., Lin, Y.J.J., Ravis, W.R., Chadha, G., Parsons, D.L., Rangari, V.K., Wright, N., Babu, R.J.: Gefitinib-cyclodextrin inclusion complexes: physico-chemical characterization and dissolution studies. Drug Dev. Ind. Pharm. 35, 1113–1120 (2009)

    Article  Google Scholar 

  19. Kim, C., Shah, B.P., Subramaniam, P., Lee, K.-B.: Synergistic induction of apoptosis in brain cancer cells by targeted codelivery of sirna and anticancer drugs. Mol. Pharm. 8, 1955–1961 (2011)

    Article  CAS  Google Scholar 

  20. Suárez, D.F., Consuegra, J., Trajano, V.C., Gontijo, S.M.L., Guimarães, P.P.G., Cortés, M.E., Denadai, Â.L., Sinisterra, R.D.: Structural and thermodynamic characterization of doxycycline/β-cyclodextrin supramolecular complex and its bacterial membrane interactions. Colloids Surf. B 118, 194–201 (2014)

    Article  Google Scholar 

  21. Gontijo, S.M.L., Gomes, A.D.M., Gala-Garcia, A., Sinisterra, R.D., Cortes, M.E.: Evaluation of antimicrobial activity and cell viability of aloe vera sponges. Electron. J. Biotechnol. 16, 10 (2013)

    Google Scholar 

  22. Guimaraes, Goulart, Guimaraes, Goulart, Guimaraes, Goulart, Guimaraes, Goulart, Guimaraes, Goulart, Guimaraes, P.P.G., Oliveira, S.R., de Castro Rodrigues, G., Gontijo, S.M.L., Lula, I.S., Cortes, M.E., Leite Denadai, A.M., Sinisterra, R.D.: Development of sulfadiazine-decorated plga nanoparticles loaded with 5-fluorouracil and cell viability. Molecules 20, 879–899 (2015)

    Article  Google Scholar 

  23. Lobaina, T., Zhurbenko, R., Alfonso, I., Rodriguez, C., Gala-Garcia, A., Gontijo, S.L., Cortes, M.E., Gomes, A., Sinisterra, R.D.: Efficacy of coral-hydroxyapatite and biphasic calcium phosphate for early bacterial detection. Biointerphases 9, 7 (2014)

    Article  Google Scholar 

  24. Bax, A., Davis, D.G.: Practical aspects of two-dimensional transverse noe spectroscopy. J. Magn. Reson. 63, 207–213 (1985)

    CAS  Google Scholar 

  25. Denadai, A.M.L., Santoro, M.M., Da Silva, L.H., Viana, A.T., Santos, R.A.S., Sinisterra, R.D.: Self-assembly characterization of the beta-cyclodextrin and hydrochlorothiazide system: Nmr, phase solubility, itc and qels. J. Incl. Phenom. Macrocycl. Chem. 55, 41–49 (2006)

    Article  CAS  Google Scholar 

  26. Higuchi, T., Connors, K.A.: Phase solubility techniques. Adv. Anal. Chem. Instr. 4, 117–212 (1965)

    CAS  Google Scholar 

  27. Qiu, N., Cheng, X., Wang, G.C., Wang, W.W., Wen, J.L., Zhang, Y.K., Song, H., Ma, L., Wei, Y.Q., Peng, A.H., Chen, L.J.: Inclusion complex of barbigerone with hydroxypropyl-beta-cyclodextrin: preparation and in vitro evaluation. Carbohydr. Polym. 101, 623–630 (2014)

    Article  CAS  Google Scholar 

  28. Du, H.Y., Xu, B., Wu, C.X., Li, M., Ran, F.X., Cai, S.Q., Cui, J.R.: Effects of cs-1 on a431 cell proliferation, cell cycle, and epidermal growth factor receptor signal transduction. Acta Biochim. Biophys. Sin. 44, 136–146 (2012)

    Article  CAS  Google Scholar 

  29. Ling, Y.H., Li, T.H., Yuan, Z.Q., Haigentz, M., Weber, T.K., Perez-Soler, R.: Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27(kip1) up-regulation and nuclear translocation in association with cell growth inhibition and g1/s phase arrest in human non-small-cell lung cancer cell lines. Mol. Pharmacol. 72, 248–258 (2007)

    Article  CAS  Google Scholar 

  30. Iacovino, R., Caso, J.V., Rapuano, F., Russo, A., Isidori, M., Lavorgna, M., Malgieri, G., Isernia, C.: Physicochemical characterization and cytotoxic activity evaluation of hydroxymethylferrocene:beta-cyclodextrin inclusion complex. Molecules 17, 6056–6070 (2012)

    Article  CAS  Google Scholar 

  31. Mendes, J.B., Rocha, M.A., Araujo, F.A., Moura, S.A.L., Ferreira, M., Andrade, S.P.: Differential effects of rolipram on chronic subcutaneous inflammatory angiogenesis and on peritoneal adhesion in mice. Microvasc. Res. 78, 265–271 (2009)

    Article  CAS  Google Scholar 

  32. Castro, P.R., Marques, S.M., Campos, P.P., Cardoso, C.C., Sampaio, F.P., Ferreira, M., Andrade, S.P.: Kinetics of implant-induced inflammatory angiogenesis in abdominal muscle wall in mice. Microvasc. Res. 84, 9–15 (2012)

    Article  CAS  Google Scholar 

  33. Marques, S.M., Campos, P.P., Castro, P.R., Cardoso, C.C., Ferreira, M., Andrade, S.P.: Genetic background determines mouse strain differences in inflammatory angiogenesis. Microvasc. Res. 82, 246–252 (2011)

    Article  CAS  Google Scholar 

  34. Boehrer, S., Ades, L., Braun, T., Galluzzi, L., Grosjean, J., Fabre, C., Le Roux, G., Gardin, C., Martin, A., de Botton, S., Fenaux, P., Kroemer, G.: Erlotinib exhibits antineoplastic off-target effects in aml and mds: a preclinical study. Blood 111, 2170–2180 (2008)

    Article  CAS  Google Scholar 

  35. Teixeira, A.S., Araujo, F.A., Ferreira, M., Barcelos, L.S., Teixeira, M.M., Andrade, S.P.: Angiogenesis and inflammation in skeletal muscle in response to ascites tumor in mice. Life Sci. 78, 1637–1645 (2006)

    Article  CAS  Google Scholar 

  36. Garnero, C., Zoppi, A., Genovese, D., Longhi, M.: Studies on trimethoprim:hydroxypropyl-beta-cyclodextrin: aggregate and complex formation. Carbohydr. Res. 345, 2550–2556 (2010)

    Article  CAS  Google Scholar 

  37. Passos, J.J., De Sousa, F.B., Mundim, I.M., Bonfim, R.R., Melo, R., Viana, A.F., Stolz, E.D., Borsoi, M., Rates, S.M.K., Sinisterra, R.D.: In vivo evaluation of the highly soluble oral beta-cyclodextrin-sertraline supramolecular complexes. Int. J. Pharm. 436, 478–485 (2012)

    Article  CAS  Google Scholar 

  38. Tien, Y.C., Su, C.S., Lien, L.H., Chen, Y.P.: Recrystallization of erlotinib hydrochloride and fulvestrant using supercritical antisolvent process. J. Supercrit. Fluids 55, 292–299 (2010)

    Article  CAS  Google Scholar 

  39. Veiga, F.J.B., Fernandes, C.M., Carvalho, R.A., Geraldes, C.: Molecular modelling and h-1-nmr: ultimate tools for the investigation of tolbutamide:Beta-cyclodextrin and tolbutamide:Hydroxypropyl-beta-cyclodextrin complexes. Chem. Pharm. Bull. 49, 1251–1256 (2001)

    Article  CAS  Google Scholar 

  40. Kim, J.H., Lee, S.K., Ki, M.H., Choi, W.K., Ahn, S.K., Shin, H.J., Hong, C.I.: Development of parenteral formulation for a novel angiogenesis inhibitor, ckd-732 through complexation with hydroxypropyl-beta-cyclodextrin. Int. J. Pharm. 272, 79–89 (2004)

    Article  CAS  Google Scholar 

  41. Connors, K.A.: The stability of cyclodextrin complexes in solution. Chem. Rev. 97, 1325–1357 (1997)

    Article  CAS  Google Scholar 

  42. Patel, R.P., Patel, M.M.: Preparation and evaluation of inclusion complex of the lipid lowering drug lovastatin with β-cyclodextrin. Dhaka Univ. J. Pharm. Sci. 6, 25–36 (2007)

    Article  Google Scholar 

  43. Turnbull, W.B., Daranas, A.H.: On the value of c: can low affinity systems be studied by isothermal titration calorimetry? J. Am. Chem. Soc. 125, 14859–14866 (2003)

    Article  CAS  Google Scholar 

  44. Rekharsky, M.V., Inoue, Y.: Complexation thermodynamics of cyclodextrins. Chem. Rev. 98, 1875–1917 (1998)

    Article  CAS  Google Scholar 

  45. de Paula, W.X., Denadai, A.M.L., Santoro, M.M., Braga, A.N.G., Santos, R.A.S., Sinisterra, R.D.: Supramolecular interactions between losartan and hydroxypropyl-beta-cd: esi mass-spectrometry, nmr techniques, phase solubility, isothermal titration calorimetry and anti-hypertensive studies. Int. J. Pharm. 404, 116–123 (2011)

    Article  Google Scholar 

  46. Rekharsky, M., Inoue, Y., Tobey, S., Metzger, A., Anslyn, E.: Ion-pairing molecular recognition in water: aggregation at low concentrations that is entropy-driven. J. Am. Chem. Soc. 124, 14959–14967 (2002)

    Article  CAS  Google Scholar 

  47. Bliesath, J., Huser, N., Omori, M., Bunag, D., Proffitt, C., Streiner, N., Ho, C., Siddiqui-Jain, A., O’Brien, S.E., Lim, J.K.C., Ryckman, D.M., Anderes, K., Rice, W.G., Drygin, D.: Combined inhibition of egfr and ck2 augments the attenuation of pi3k-akt-mtor signaling and the killing of cancer cells. Cancer Lett. 322, 113–118 (2012)

    Article  CAS  Google Scholar 

  48. Kim, J.C., Ali, M.A., Nandi, A., Mukhopadhyay, P., Choy, H., Cao, C., Saha, D.: Correlation of her1/egfr expression and degree of radiosensitizing effect of the her1/egfr-tyrosine kinase inhibitor erlotinib. Indian J. Biochem. Biophys. 42, 358–365 (2005)

    CAS  Google Scholar 

  49. Li, D.D., Fang, F., Li, J.R., Du, Q.R., Sun, J., Gong, H.B., Zhu, H.L.: Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel egfr tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett. 22, 5870–5875 (2012)

    Article  CAS  Google Scholar 

  50. Yamasaki, F., Zhang, D.W., Bartholomeusz, C., Sudo, T., Hortobagyi, G.N., Kurisu, K., Ueno, N.T.: Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Mol. Cancer Ther. 6, 2168–2177 (2007)

    Article  CAS  Google Scholar 

  51. Dehelean, C.A., Soica, C., Peev, C., Ciurlea, S., Feflea, S., Kasa, P.: A pharmaco-toxicological evaluation of betulinic acid mixed with hydroxipropilgamma cyclodextrin on in vitro and in vivo models. Farmacia 59, 51–59 (2011)

    CAS  Google Scholar 

  52. Hovgaard, L.: Drug-delivery studies in caco-2 monolayers.4. Absorption enhancer effects of cyclodextrins. Pharm. Res. 12, 1328–1332 (1995)

    Article  CAS  Google Scholar 

  53. Irie, T., Uekama, K.: Cyclodextrins in peptide and protein delivery. Adv. Drug Deliv. Rev. 36, 101–123 (1999)

    Article  CAS  Google Scholar 

  54. Ohtani, Y., Irie, T., Uekama, K., Fukunaga, K., Pitha, J.: Differential-effects of alpha-cyclodextrins, beta-cyclodextrins and gamma-cyclodextrins on human-erythrocytes. Eur. J. Biochem. 186, 17–22 (1989)

    Article  CAS  Google Scholar 

  55. Björkelund, H., Gedda, L., Malmqvist, M., Andersson, K.: Resolving the egf-egfr interaction characteristics through a multiple-temperature, multiple-inhibitor, real-time interaction analysis approach. Mol. Clin. Oncol. 1, 343–352 (2013)

    Google Scholar 

  56. Folkman, J.: Endogenous angiogenesis inhibitors. Apmis 112, 496–507 (2004)

    Article  CAS  Google Scholar 

  57. Yano, H., Hirayama, F., Arima, H., Uekama, K.: Prednisolone-appended alpha-cyclodextrin: alleviation of systemic adverse effect of prednisolone after intracolonic administration in 2,4,6-trinitrobenzenesulfonic acid-induced colitis rats. J. Pharm. Sci. 90, 2103–2112 (2001)

    Article  CAS  Google Scholar 

Download references

Acknowledgments

We are grateful for CAPES, CNPq, FINEP, FAPEMIG, PRPq, INCT/Nanobiofar, CNPq Nanofar network that support this investigation.

Author information

Authors and Affiliations

  1. Restorative Dentistry Department, Faculty of Dentistry, Universidade Federal de Minas Gerais, Av. Antônio Carlos 6627, Belo Horizonte, MG, CEP 31270-901, Brazil

    Sávio M. L. Gontijo & Maria E. Cortés

  2. Chemistry Department, Institute of Exact Sciences, Universidade Federal de Minas Gerais, Av. Antônio Carlos 6627, Belo Horizonte, MG, CEP 31270-901, Brazil

    Pedro P. G. Guimarães, Alinne D. M. Gomes & Rubén D. Sinisterra

  3. Department of Physiology and Biophysics, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Av. Antônio Carlos 6627, Belo Horizonte, MG, CEP 31270-901, Brazil

    Celso T. R. Viana & Silvia P. Andrade

  4. Department of Pharmacy, Universidade Federal de Juiz de Fora, Av. Dr. Raimundo Monteiro de Rezende 330, Governador Valadares, MG, CEP 35010-177, Brazil

    Ângelo M. L. Denadai

  5. Department of General Pathology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Av. Antônio Carlos 6627, Belo Horizonte, MG, CEP 31270-901, Brazil

    Paula P. Campos

Authors
  1. Sávio M. L. Gontijo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pedro P. G. Guimarães
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Celso T. R. Viana
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ângelo M. L. Denadai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alinne D. M. Gomes
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Paula P. Campos
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Silvia P. Andrade
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Rubén D. Sinisterra
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Maria E. Cortés
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria E. Cortés.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gontijo, S.M.L., Guimarães, P.P.G., Viana, C.T.R. et al. Erlotinib/hydroxypropyl-β-cyclodextrin inclusion complex: characterization and in vitro and in vivo evaluation. J Incl Phenom Macrocycl Chem 83, 267–279 (2015). https://doi.org/10.1007/s10847-015-0562-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10847-015-0562-3

Keywords

Search

Navigation